{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:34:39Z","timestamp":1793147679968,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Imam Mohammed Ibn Saud Islamic University","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01582-z","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:34:19Z","timestamp":1756938859000},"page":"1109-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting the TRIB3\u2013MYC axis in cancer: mechanistic insights and therapeutic disruption strategies"],"prefix":"10.1007","volume":"43","author":[{"given":"Emadeldin M.","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman A.","family":"Alsalamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris F. Aba","family":"Alkhayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Mokhtar","family":"Lamsabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"6","key":"1582_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/1541-7786.MCR-13-0536","volume":"12","author":"H Beltran","year":"2014","unstructured":"Beltran H (2014) The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res 12(6):815\u2013822","journal-title":"Mol Cancer Res"},{"issue":"3","key":"1582_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tcb.2022.07.006","volume":"33","author":"SK Das","year":"2023","unstructured":"Das SK, Lewis BA, Levens D (2023) MYC: a complex problem. Trends Cell Biol 33(3):235\u2013246","journal-title":"Trends Cell Biol"},{"key":"1582_CR3","doi-asserted-by":"crossref","unstructured":"Zhou, Y., et al., Targeting Myc interacting proteins as a winding path in cancer therapy. Frontiers in Pharmacology, 2021. Volume 12 - 2021.","DOI":"10.3389\/fphar.2021.748852"},{"issue":"5","key":"1582_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbagrm.2014.06.002","volume":"1849","author":"WB Tu","year":"2015","unstructured":"Tu WB et al (2015) Myc and its interactors take shape. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1849(5):469\u2013483","journal-title":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"},{"issue":"9","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","volume":"21","author":"C Lourenco","year":"2021","unstructured":"Lourenco C et al (2021) MYC protein interactors in gene transcription and cancer. Nat Rev Cancer 21(9):579\u2013591","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1582_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06627-4","volume":"15","author":"J Li","year":"2024","unstructured":"Li J et al (2024) Trib3 promotes the progression of renal cell carcinoma by upregulating the lipid droplet-associated protein PLIN2. Cell Death Dis 15(4):240","journal-title":"Cell Death Dis"},{"issue":"1","key":"1582_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20107-1","volume":"11","author":"K Li","year":"2020","unstructured":"Li K et al (2020) Trib3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation. Nat Commun 11(1):6316","journal-title":"Nat Commun"},{"issue":"45","key":"1582_CR8","doi-asserted-by":"publisher","first-page":"72415","DOI":"10.18632\/oncotarget.11719","volume":"7","author":"A D\u2019Andrea","year":"2016","unstructured":"D\u2019Andrea A et al (2016) The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. Oncotarget 7(45):72415\u201372430","journal-title":"Oncotarget"},{"issue":"3","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E et al (2024) MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med 30(3):762\u2013771","journal-title":"Nat Med"},{"issue":"3","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.apsb.2021.09.014","volume":"12","author":"M-X Su","year":"2022","unstructured":"Su M-X et al (2022) C-MYC-mediated TRIB3\/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. Acta Pharm Sin B 12(3):1240\u20131253","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"1582_CR11","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/acs.accounts.7b00130","volume":"50","author":"N Sawyer","year":"2017","unstructured":"Sawyer N, Watkins AM, Arora PS (2017) Protein domain mimics as modulators of protein\u2013protein interactions. Acc Chem Res 50(6):1313\u20131322","journal-title":"Acc Chem Res"},{"key":"1582_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aau0597","author":"SA Jamieson","year":"2018","unstructured":"Jamieson SA et al (2018) Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. Sci Signal. https:\/\/doi.org\/10.1126\/scisignal.aau0597","journal-title":"Sci Signal"},{"issue":"5","key":"1582_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.str.2016.03.002","volume":"24","author":"S Uljon","year":"2016","unstructured":"Uljon S et al (2016) Structural basis for substrate selectivity of the E3 ligase COP1. Structure 24(5):687\u2013696","journal-title":"Structure"},{"issue":"11","key":"1582_CR14","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.str.2015.08.017","volume":"23","author":"JM Murphy","year":"2015","unstructured":"Murphy JM et al (2015) Molecular mechanism of CCAAT-enhancer binding protein recruitment by the TRIB1 pseudokinase. Structure 23(11):2111\u20132121","journal-title":"Structure"},{"key":"1582_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081822","author":"B Stefanovska","year":"2021","unstructured":"Stefanovska B, Andr\u00e9 F, Fromigu\u00e9 O (2021) Tribbles pseudokinase 3 regulation and contribution to cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081822","journal-title":"Cancers (Basel)"},{"issue":"18","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/sj.onc.1206367","volume":"22","author":"AJ Bowers","year":"2003","unstructured":"Bowers AJ, Scully S, Boylan JF (2003) SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia. Oncogene 22(18):2823\u20132835","journal-title":"Oncogene"},{"issue":"41","key":"1582_CR17","doi-asserted-by":"publisher","first-page":"42703","DOI":"10.1074\/jbc.M407732200","volume":"279","author":"E Kiss-Toth","year":"2004","unstructured":"Kiss-Toth E et al (2004) Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem 279(41):42703\u201342708","journal-title":"J Biol Chem"},{"key":"1582_CR18","doi-asserted-by":"crossref","unstructured":"Bhuyan, P., et al., Computational analysis of MYC gene variants: structural and functional impact of non-synonymous SNPs. Journal of Applied Genetics, 2024.","DOI":"10.1007\/s13353-024-00929-1"},{"issue":"6","key":"1582_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06844-x","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S et al (2024) VHL suppresses UBE3B-mediated breast tumor growth and metastasis. Cell Death Dis 15(6):446","journal-title":"Cell Death Dis"},{"issue":"7","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-18-2049","volume":"79","author":"L Wu","year":"2019","unstructured":"Wu L et al (2019) Loss of FOXP3 and TSC1 accelerates prostate cancer progression through synergistic transcriptional and posttranslational regulation of c-MYC. Cancer Res 79(7):1413\u20131425","journal-title":"Cancer Res"},{"issue":"2","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41418-019-0363-0","volume":"27","author":"Q Zhang","year":"2020","unstructured":"Zhang Q et al (2020) The MAP3K13-TRIM25-FBXW7\u03b1 axis affects c-Myc protein stability and tumor development. Cell Death Differ 27(2):420\u2013433","journal-title":"Cell Death Differ"},{"issue":"1","key":"1582_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00500-y","volume":"6","author":"C Wang","year":"2021","unstructured":"Wang C et al (2021) Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther 6(1):117","journal-title":"Signal Transduct Target Ther"},{"key":"1582_CR23","doi-asserted-by":"crossref","unstructured":"Shang, S., et al., TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer. Science Translational Medicine, 2022. 14(626): p. eabf0992.","DOI":"10.1126\/scitranslmed.abf0992"},{"issue":"4","key":"1582_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040883","volume":"9","author":"D Mass\u00f3-Vall\u00e9s","year":"2020","unstructured":"Mass\u00f3-Vall\u00e9s D, Soucek L (2020) Blocking myc to treat cancer: reflecting on two decades of Omomyc. Cells 9(4):883","journal-title":"Cells"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0959-8049(22)00820-6","volume":"174","author":"E Garralda","year":"2022","unstructured":"Garralda E et al (2022) Dose escalation study of OMO-103, a first in class pan-MYC-inhibitor in patients (pts) with advanced solid tumors. Eur J Cancer 174:S5\u2013S6","journal-title":"Eur J Cancer"},{"issue":"3","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s13402-023-00777-x","volume":"46","author":"Q Zou","year":"2023","unstructured":"Zou Q et al (2023) E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities. Cell Oncol 46(3):545\u2013570","journal-title":"Cell Oncol"},{"issue":"24","key":"1582_CR27","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","volume":"101","author":"M Welcker","year":"2004","unstructured":"Welcker M et al (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A 101(24):9085\u20139090","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1582_CR28","doi-asserted-by":"crossref","unstructured":"Yada, M., et al., Phosphorylation\u2010dependent degradation of c\u2010Myc is mediated by the F\u2010box protein Fbw7. The EMBO Journal, 2004. 23(10): p. 2116\u20132125\u20132125.","DOI":"10.1038\/sj.emboj.7600217"},{"issue":"36","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"38591","DOI":"10.18632\/oncotarget.5774","volume":"6","author":"Q Cai","year":"2015","unstructured":"Cai Q et al (2015) MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget 6(36):38591\u201338616","journal-title":"Oncotarget"},{"issue":"46","key":"1582_CR30","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1038\/s41388-023-02842-z","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y et al (2023) UBE3B promotes breast cancer progression by antagonizing HIF-2\u03b1 degradation. Oncogene 42(46):3394\u20133406","journal-title":"Oncogene"},{"issue":"8","key":"1582_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1080\/15384047.2019.1595283","volume":"20","author":"I Sahin","year":"2019","unstructured":"Sahin I et al (2019) Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther 20(8):1047\u20131056","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"1582_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124265","volume":"21","author":"E Vecchio","year":"2020","unstructured":"Vecchio E et al (2020) Insights about MYC and apoptosis in B-lymphomagenesis: an update from murine models. Int J Mol Sci 21(12):4265","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1582_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001778","volume":"21","author":"T-Y Lim","year":"2023","unstructured":"Lim T-Y et al (2023) Txnip loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding. PLoS Biol 21(3):e3001778","journal-title":"PLoS Biol"},{"issue":"1","key":"1582_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30257-z","volume":"13","author":"X Qiu","year":"2022","unstructured":"Qiu X et al (2022) MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nat Commun 13(1):2559","journal-title":"Nat Commun"},{"key":"1582_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113137","volume":"213","author":"J Ross","year":"2021","unstructured":"Ross J et al (2021) Targeting MYC: from understanding its biology to drug discovery. Eur J Med Chem 213:113137","journal-title":"Eur J Med Chem"},{"issue":"10","key":"1582_CR36","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1038\/s41375-019-0454-4","volume":"33","author":"CT Harrington","year":"2019","unstructured":"Harrington CT et al (2019) Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia 33(10):2429\u20132441","journal-title":"Leukemia"},{"issue":"9","key":"1582_CR37","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/onc.2009.512","volume":"29","author":"WC Gustafson","year":"2010","unstructured":"Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29(9):1249\u20131259","journal-title":"Oncogene"},{"issue":"20","key":"1582_CR38","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.15687","volume":"8","author":"S Shang","year":"2017","unstructured":"Shang S, Hua F, Hu ZW (2017) The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8(20):33972\u201333989","journal-title":"Oncotarget"},{"issue":"35","key":"1582_CR39","doi-asserted-by":"publisher","first-page":"58847","DOI":"10.18632\/oncotarget.19375","volume":"8","author":"M Zhao","year":"2017","unstructured":"Zhao M et al (2017) Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget 8(35):58847\u201358864","journal-title":"Oncotarget"},{"issue":"4","key":"1582_CR40","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3892\/or.2016.5017","volume":"36","author":"S Dong","year":"2016","unstructured":"Dong S et al (2016) Overexpression of TRIB3 promotes angiogenesis in human gastric cancer. Oncol Rep 36(4):2339\u20132348","journal-title":"Oncol Rep"},{"issue":"3","key":"1582_CR41","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/j.gastro.2018.10.031","volume":"156","author":"F Hua","year":"2019","unstructured":"Hua F et al (2019) TRIB3 interacts with & #x3b2;-catenin and TCF4 to increase stem cell features of colorectal cancer stem cells and tumorigenesis. Gastroenterology 156(3):708-721.e15","journal-title":"Gastroenterology"},{"issue":"1","key":"1582_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17385-0","volume":"11","author":"J-J Yu","year":"2020","unstructured":"Yu J-J et al (2020) Trib3-EGFR interaction promotes lung cancer progression and defines a therapeutic target. Nat Commun 11(1):3660","journal-title":"Nat Commun"},{"issue":"6","key":"1582_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tips.2024.04.008","volume":"45","author":"PE Thompson","year":"2024","unstructured":"Thompson PE, Shortt J (2024) Defeating MYC with drug combinations or dual-targeting drugs. Trends Pharmacol Sci 45(6):490\u2013502","journal-title":"Trends Pharmacol Sci"},{"key":"1582_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010002","author":"LM Moreno-Vargas","year":"2024","unstructured":"Moreno-Vargas LM, Prada-Gracia D (2024) Cancer-targeting applications of cell-penetrating peptides. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26010002","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1582_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/carcin\/bgae042","volume":"45","author":"S Lei","year":"2024","unstructured":"Lei S et al (2024) Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target. Carcinogenesis 45(8):527\u2013542","journal-title":"Carcinogenesis"},{"key":"1582_CR46","doi-asserted-by":"crossref","unstructured":"Cheng, X., et al., Parishin B blocking TRIB3-AKT1 interaction inhibits breast cancer lung metastasis. Frontiers in Pharmacology, 2025. Volume 15 - 2024.","DOI":"10.3389\/fphar.2024.1517708"},{"key":"1582_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216978","volume":"594","author":"B Li","year":"2024","unstructured":"Li B, Eichhorn PJA, Chng W-J (2024) Targeting the ubiquitin pathway in lymphoid malignancies. Cancer Lett 594:216978","journal-title":"Cancer Lett"},{"issue":"11","key":"1582_CR48","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.str.2022.08.006","volume":"30","author":"SA Jamieson","year":"2022","unstructured":"Jamieson SA et al (2022) Nanobodies identify an activated state of the TRIB2 pseudokinase. Structure 30(11):1518-1529.e5","journal-title":"Structure"},{"issue":"11","key":"1582_CR49","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.str.2022.10.006","volume":"30","author":"FR Santana","year":"2022","unstructured":"Santana FR, Linossi EM, Jura N (2022) Trapping tribbles: nanobody-assisted structure of the TRIB2 pseudokinase. Structure 30(11):1465\u20131467","journal-title":"Structure"},{"issue":"11","key":"1582_CR50","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.chembiol.2019.08.009","volume":"26","author":"N Bery","year":"2019","unstructured":"Bery N et al (2019) A targeted protein degradation cell-based screening for nanobodies selective toward the cellular RHOB GTP-bound conformation. Cell Chem Biol 26(11):1544-1558.e6","journal-title":"Cell Chem Biol"},{"issue":"4","key":"1582_CR51","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI et al (2024) Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med 56(4):836\u2013849","journal-title":"Exp Mol Med"},{"issue":"1","key":"1582_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02298-7","volume":"22","author":"Q Yang","year":"2024","unstructured":"Yang Q et al (2024) Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application. J Nanobiotechnology 22(1):41","journal-title":"J Nanobiotechnology"},{"key":"1582_CR53","doi-asserted-by":"crossref","unstructured":"Porello, I. and F. Cellesi, Intracellular delivery of therapeutic proteins. New advancements and future directions. Frontiers in Bioengineering and Biotechnology, 2023. Volume 11 - 2023.","DOI":"10.3389\/fbioe.2023.1211798"},{"issue":"18","key":"1582_CR54","doi-asserted-by":"publisher","first-page":"21877","DOI":"10.1021\/acsami.3c01501","volume":"15","author":"RM Haley","year":"2023","unstructured":"Haley RM et al (2023) Lipid nanoparticle delivery of small proteins for potent in vivo RAS inhibition. ACS Appl Mater Interfaces 15(18):21877\u201321892","journal-title":"ACS Appl Mater Interfaces"},{"issue":"24","key":"1582_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249486","volume":"21","author":"J McAnulty","year":"2020","unstructured":"McAnulty J, DiFeo A (2020) The molecular \u2018Myc-anisms\u2019 behind Myc-driven tumorigenesis and the relevant Myc-directed therapeutics. Int J Mol Sci 21(24):9486","journal-title":"Int J Mol Sci"},{"key":"1582_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.abb.2017.04.008","volume":"622","author":"IJ Wu","year":"2017","unstructured":"Wu IJ et al (2017) Trib3 downregulation enhances doxorubicin-induced cytotoxicity in gastric cancer cells. Arch Biochem Biophys 622:26\u201335","journal-title":"Arch Biochem Biophys"},{"key":"1582_CR57","doi-asserted-by":"crossref","unstructured":"Lau, Y., et al., ChemInform abstract: peptide stapling techniques based on different macrocyclization chemistries. Chemical Society reviews, 2014. 44.","DOI":"10.1039\/C4CS00246F"},{"key":"1582_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1296091","volume":"14","author":"I Waheed","year":"2024","unstructured":"Waheed I et al (2024) Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol 14:1296091","journal-title":"Front Oncol"},{"key":"1582_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540192","volume":"16","author":"JJ Du","year":"2025","unstructured":"Du JJ et al (2025) Applications of cell penetrating peptide-based drug delivery system in immunotherapy. Front Immunol 16:1540192","journal-title":"Front Immunol"},{"key":"1582_CR60","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2024.08.009","volume":"374","author":"S Bibb\u00f2","year":"2024","unstructured":"Bibb\u00f2 S et al (2024) EV20\/Omomyc: a novel dual MYC\/HER3 targeting immunoconjugate. J Control Release 374:171\u2013180","journal-title":"J Control Release"},{"issue":"8","key":"1582_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081636","volume":"14","author":"S Kotta","year":"2022","unstructured":"Kotta S et al (2022) Progress in polymeric micelles for drug delivery applications. Pharmaceutics 14(8):1636","journal-title":"Pharmaceutics"},{"key":"1582_CR62","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2024.2436391","author":"K Yang","year":"2024","unstructured":"Yang K et al (2024) Trib3 overexpression predicts malignant progression and poor prognosis in human solid tumors: bioinformatics validation and clinical significance. Expert Rev Mol Diagn. https:\/\/doi.org\/10.1080\/14737159.2024.2436391","journal-title":"Expert Rev Mol Diagn"},{"key":"1582_CR63","doi-asserted-by":"crossref","unstructured":"Wu, H., et al., TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion. Frontiers in Immunology, 2024. Volume 14 - 2023.","DOI":"10.3389\/fimmu.2023.1290839"},{"issue":"7","key":"1582_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jics.2022.100531","volume":"99","author":"G Lanka","year":"2022","unstructured":"Lanka G et al (2022) Targeting Tribbles homolog 3 (TRIB3) protein against type 2 diabetes for the identification of potential inhibitors by in silico screening. J Indian Chem Soc 99(7):100531","journal-title":"J Indian Chem Soc"},{"issue":"1","key":"1582_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45766-2","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S et al (2024) Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations. Nat Commun 15(1):1611","journal-title":"Nat Commun"},{"key":"1582_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111783","volume":"132","author":"B O\u2019Gorman","year":"2025","unstructured":"O\u2019Gorman B, Cooke SF, Blair CM (2025) Precision peptide disruptors: the next generation of targeted therapeutics in oncology. Cell Signal 132:111783","journal-title":"Cell Signal"},{"issue":"22","key":"1582_CR67","doi-asserted-by":"publisher","first-page":"13020","DOI":"10.1021\/acs.chemrev.4c00423","volume":"124","author":"CS Swenson","year":"2024","unstructured":"Swenson CS et al (2024) Tackling undruggable targets with designer peptidomimetics and synthetic biologics. Chem Rev 124(22):13020\u201313093","journal-title":"Chem Rev"},{"issue":"11","key":"1582_CR68","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","volume":"69","author":"C Zhang","year":"2024","unstructured":"Zhang C et al (2024) Targeting the undruggables\u2014the power of protein degraders. Sci Bull 69(11):1776\u20131797","journal-title":"Sci Bull"},{"key":"1582_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105403","volume":"145","author":"DD Martinelli","year":"2022","unstructured":"Martinelli DD (2022) Generative machine learning for de novo drug discovery: a systematic review. Comput Biol Med 145:105403","journal-title":"Comput Biol Med"},{"issue":"1","key":"1582_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-023-00711-1","volume":"15","author":"X Liu","year":"2023","unstructured":"Liu X et al (2023) Molfiltergan: a progressively augmented generative adversarial network for triaging AI-designed molecules. J Cheminform 15(1):42","journal-title":"J Cheminform"},{"issue":"10","key":"1582_CR71","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/17425247.2022.2106213","volume":"19","author":"C Bassand","year":"2022","unstructured":"Bassand C et al (2022) Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities. Expert Opin Drug Deliv 19(10):1265\u20131283","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"1582_CR72","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers17010010","volume":"17","author":"L Mavroeidis","year":"2025","unstructured":"Mavroeidis L et al (2025) Novel therapeutics in soft tissue sarcoma. Cancers 17(1):10","journal-title":"Cancers"},{"key":"1582_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117016","volume":"281","author":"C Wen","year":"2025","unstructured":"Wen C et al (2025) Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2. Eur J Med Chem 281:117016","journal-title":"Eur J Med Chem"},{"issue":"1","key":"1582_CR74","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-025-01674-6","volume":"18","author":"N Li","year":"2025","unstructured":"Li N, Sheng J, Zhu H-H (2025) Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024. J Hematol Oncol 18(1):26","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1582_CR75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acs.biochem.4c00577","volume":"64","author":"K Berkley","year":"2025","unstructured":"Berkley K et al (2025) Journey of PROTAC: from bench to clinical trial and beyond. Biochemistry 64(3):563\u2013580","journal-title":"Biochemistry"},{"key":"1582_CR76","doi-asserted-by":"crossref","unstructured":"Vetma, V., et al., Development of PROTAC degrader drugs for cancer. Annual Review of Cancer Biology, 2025. 9(Volume 9, 2025): p. 119\u2013140.","DOI":"10.1146\/annurev-cancerbio-061824-105806"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01582-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01582-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:39Z","timestamp":1760195019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01582-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01582-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}